At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine.

There is a compelling need to produce new antibiotics that hamper severe opportunistic infections, especially in immunocompromised individuals, such as those caused by gram-negative Pseudomonas aeruginosa.

Amicetin-inspired inhibitors of the P-site (AIIPS), also known as CZ-02s, are a series of molecules that target and inhibit a unique site of the bacterial ribosome.

There is still a need for developing more potent and broadly neutralizing vaccines against SARS-CoV-2 with improved durability. At the recent ESCMID meeting, Astrazeneca plc presented a new mRNA vaccine against the SARS-CoV-2 virus that encodes for self-assembling virus-like particle (VLP) antigens.

Debiopharm International SA has developed and presented a Fabl inhibitor, gofabicin, for the treatment of antibiotic-resistant Neisseria gonorrhoeae.

Researchers from Tan Tock Seng Hospital presented data from a study investigating the utility of soluble suppressor of tumorigenicity-2 (sST2) as early prognostic biomarker of severe dengue.

Current approved antifungal therapies are limited by their associated adverse events. SCY-247 is a new triterpenoid antifungal for intravenous or oral administration that inhibits the glucan synthase enzyme, which is a key member for the fungal cell wall.

Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne disease that results from an infection with the SFTS virus, with a case fatality rate of 6.1% to 21.8%. Identifying critically ill patients at the early stages is crucial for clinical management.

Researchers from Longhorn Vaccines & Diagnostics LLC have presented data at the ongoing ESCMID conference regarding their unconjugated multiepitope vaccine against influenza, LHNVD-105.